100 related articles for article (PubMed ID: 21762788)
1. The Primavera study protocol design: evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non-anemic patients with chronic kidney disease.
Fliser D; Dellanna F; Koch M; Seufert J; Witzke O; Hauser IA
Contemp Clin Trials; 2011 Nov; 32(6):786-92. PubMed ID: 21762788
[TBL] [Abstract][Full Text] [Related]
2. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
4. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
5. Anemia control in renal transplant recipients receiving continuous erythropoietin receptor activator (C.E.R.A.) treatment: the AnemiaTrans Study.
Sánchez-Fructuoso AI; Ruiz JC; Torregrosa JV; González E; Gómez E; Gallego RJ; Troya MI; Jimenez C; Llamas F; Romero R; Bernis C; Crespo JF; Guirado L;
Adv Ther; 2012 Nov; 29(11):979-91. PubMed ID: 23160946
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemia.
Chanu P; Gieschke R; Charoin JE; Pannier A; Reigner B
J Clin Pharmacol; 2010 May; 50(5):507-20. PubMed ID: 20179322
[TBL] [Abstract][Full Text] [Related]
7. Early low-dose erythropoiesis-stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo-controlled trial.
Fliser D; Dellanna F; Koch M; Wiggenhauser A;
Nephrol Dial Transplant; 2017 Feb; 32(2):279-287. PubMed ID: 28186540
[TBL] [Abstract][Full Text] [Related]
8. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.
Klinger M; Arias M; Vargemezis V; Besarab A; Sulowicz W; Gerntholtz T; Ciechanowski K; Dougherty FC; Beyer U
Am J Kidney Dis; 2007 Dec; 50(6):989-1000. PubMed ID: 18037099
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Vidt DG; Ridker PM; Monyak JT; Schreiber MJ; Cressman MD
Clin Ther; 2011 Jun; 33(6):717-25. PubMed ID: 21704236
[TBL] [Abstract][Full Text] [Related]
11. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks.
Spinowitz B; Coyne DW; Lok CE; Fraticelli M; Azer M; Dalal S; Villa G; Rosansky S; Adamis H; Beyer U;
Am J Nephrol; 2008; 28(2):280-9. PubMed ID: 18004064
[TBL] [Abstract][Full Text] [Related]
12. Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study.
de Francisco AL; Sulowicz W; Klinger M; Niemczyk S; Vargemezis V; Metivier F; Dougherty FC; Oguey D;
Int J Clin Pract; 2006 Dec; 60(12):1687-96. PubMed ID: 17109676
[TBL] [Abstract][Full Text] [Related]
13. Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study).
Hayashi T; Uemura Y; Kumagai M; Kimpara M; Kanno H; Ohashi Y;
Clin Exp Nephrol; 2019 Mar; 23(3):349-361. PubMed ID: 30291472
[TBL] [Abstract][Full Text] [Related]
14. [Incidence and management of anemia in renal transplantation: an observational-French study].
Choukroun G; Deray G; Glotz D; Lebranchu Y; Dussol B; Bourbigot B; Lefrançois N; Cassuto-Viguier E; Toupance O; Hacen C; Lang P; Mazouz H; Martinez F
Nephrol Ther; 2008 Dec; 4(7):575-83. PubMed ID: 18672417
[TBL] [Abstract][Full Text] [Related]
15. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
16. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).
Pfeffer MA; Burdmann EA; Chen CY; Cooper ME; de Zeeuw D; Eckardt KU; Ivanovich P; Kewalramani R; Levey AS; Lewis EF; McGill J; McMurray JJ; Parfrey P; Parving HH; Remuzzi G; Singh AK; Solomon SD; Toto R; Uno H;
Am J Kidney Dis; 2009 Jul; 54(1):59-69. PubMed ID: 19501439
[TBL] [Abstract][Full Text] [Related]
17. Anemia normalization in patients with type 2 diabetes and chronic kidney disease: results of the NEPHRODIAB2 randomized trial.
Villar E; Lièvre M; Kessler M; Lemaître V; Alamartine E; Rodier M; François M; Zaoui P; Moranne O; Choukroun G; Guerraoui A; Jolivot A; Janin G; Branger B; Heng AE; Boudray C; Bissery A; Rabilloud M; Pouteil-Noble C
J Diabetes Complications; 2011; 25(4):237-43. PubMed ID: 21601481
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease.
Macdougall IC; Robson R; Opatrna S; Liogier X; Pannier A; Jordan P; Dougherty FC; Reigner B
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1211-5. PubMed ID: 17699350
[TBL] [Abstract][Full Text] [Related]
19. Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials.
Locatelli F; Choukroun G; Truman M; Wiggenhauser A; Fliser D
Adv Ther; 2016 Apr; 33(4):610-25. PubMed ID: 26965694
[TBL] [Abstract][Full Text] [Related]
20. Erythropoiesis-stimulating protein therapy and the decline of renal function: a retrospective analysis of patients with chronic kidney disease.
Dean BB; Dylan M; Gano A; Knight K; Ofman JJ; Levine BS
Curr Med Res Opin; 2005 Jul; 21(7):981-7. PubMed ID: 16004664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
